Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 4, 2002, Pages 281-287

  Yan, Z ^a   Rafferty, B ^a   Caldwell, G W ^a   Masucci, J A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CYPs; Irreversible inhibition; Mechanism based inhibition

Indexed keywords

CLARITHROMYCIN; CLOTRIMAZOLE; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; ETHINYLESTRADIOL; FURAFYLLINE; KETOCONAZOLE; MICONAZOLE; MIDAZOLAM; OLEANDOMYCIN; TERFENADINE; VERAPAMIL;

ARTICLE; DRUG BINDING; DRUG DEGRADATION; DRUG METABOLISM; DRUG MONITORING; DRUG SCREENING; DRUG STABILITY; ENZYME INACTIVATION; ENZYME INHIBITION; FLUORESCENCE; FLUOROMETRY; IC 50; INCUBATION TIME; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT; METABOLITE; MICROSOME; RELIABILITY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUORESCENT DYES; KINETICS; MASS SPECTROMETRY; MICROSOMES, LIVER; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE;

EID: 0036825366     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03192339     Document Type: Article

References (22)

1. von Moltke L L; Greenblatt D J; Duan S X; Harmatz J S; Shader R I In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharm. (1994), 34(12), 1222-1227.
2. Griffin J. P. The withdrawal of mibefradil (Posicor). Adverse Drug Reactions and Toxicological Reviews (1998), 17 (2-3), 59-60.
3. Lin, J. H.; Lu, A. Y. H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. (1998), 35(5), 361-390.
4. Yan Z.; Caldwell G. W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. (2001), 1(5), 403-425.
5. Chu, I.; Favreau, L.; Soares, T.; Lin, C. C.; Nomeir, A. A. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes. Rapid Comm. in Mass Spectr. (2000), 14(4), 207-214.
6. Crespi, C. L.; Stresser, D. M. Fluorometric screening for metabolism-based drug-drug interactions. J. Pharm. Toxicol. Methods (2001), 44(1), 325-331.
7. Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. (1997), 248(1), 188-190.
8. Palamanda, J. R.; Casciano, C. N.; Norton, L. A.; Clement, R. P.; Favreau, L.; Lin, C-C; Nomeir, A. A. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazineyl] pyrimidine. Drug Metab. Despos. (2001), 29(6), 863-867.
9. Racha, J. K.; Rettie, A. E.; Kunze, K. L. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry (1998), 37(20), 7407-7419.
10. Silverman, R.B. Mechanism-based Enzyme Inactivation: Chemistry and Enzymology (vol. I) CRC Press, Inc., 1988.
11. Bennett, M.; Prueksaritanont, T.; Lin, J. H. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. (2000), 28(2), 125-130.
12. Khan, K. K.; He, Y. Q.; Domanski, T. L.; Halpert, J. R. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mole. Pharm. (2002), 61(3), 495-506.
13. Zhang, W.; Ramamoorthy, Y.; Kilicarslan, T.; Nolte, H.; Tyndale, R. F.; Sellers, E. M. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos. (2002), 30(3), 314-318.
14. Yun, C. H.; Okerholm, R. A.; Guengerich, F. P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. (1993), 21(3), 403-9.
15. Obach, R. Scott. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. (1997), 25(12), 1359-1369.
16. Lindstrom, T. D.; Hanssen, B. R.; Wrighton, S. A. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother. (1993), 37(2), 265-269.
17. Sutton D; Butler A M; Nadin L; Murray M Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharm. Exp. Ther. (1997), 282(1), 294-300.
18. Bapiro, T. E.; Egnell, A-C; Hasler, J. A.; Masimirembwa, C. M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S. Drug Metab. Dispos. (2001), 29(1), 30-35.
19. Gibbs, Megan A.; Thummel, Kenneth E.; Shen, Danny D.; Kunze, Kent L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of KI values and impact of CYP3A5 expression. Drug Metab. Dispos. (1999), 27(2), 180-187.
20. Jacobsen, W.; Kirchner, G.; Hallensleben, K.; Mancinelli, L.; Deters, M.; Hackbarth, I.; Benet, L. Z.; Sewing, K-F.; Christians, U. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Dispos. (1999), 27(2), 173-179.
21. Bachus R; Bickel U; Thomsen T; Roots I; Kewitz H The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics (1999), 9(6), 661-668.
22. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. (1996), 277(1), 321-32.